Overview

AZD9833 China PK Study

Status:
Not yet recruiting

Trial end date:
2023-08-11

Target enrollment:

Participant gender:

Summary

A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Chinese patients with ER Positive, HER2 Negative, Metastatic Breast Cancer.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Everolimus
Palbociclib